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Background: TNF--induced NF-B pathway is associated with the progression of several cancers and abrogation of TNF
signaling a potential target for cancer treatment.
Results: Novel biscoumarin inhibits TNF signaling in vitro and in vivo in IBD model.
Conclusion: The lead compound interrupts the trimeric structure of TNF to achieve this effect.
Significance: This study introduces a novel TNF inhibitor with the potential to target pro-inflammatory diseases.
TNF is a pleotropic cytokine known to be involved in the pro-
gression of several pro-inflammatory disorders. Many thera-
peutic agents have beendesigned to counteract the effect ofTNF
in rheumatoid arthritis as well as a number of cancers. In the
present studywehave synthesized and evaluated the anti-cancer
activity of novel biscoumarins in vitro and in vivo. Among new
compounds, BIHC was found to be the most cytotoxic agent
against the HepG2 cell line while exhibiting less toxicity toward
normal hepatocytes. Furthermore, BIHC inhibited the prolifer-
ation of various hepatocellular carcinoma (HCC) cells in a dose-
and time-dependent manner. Subsequently, using in silico
target prediction, BIHC was predicted as a TNF blocker. Exper-
imental validation was able to confirm this hypothesis, where
BIHC could significantly inhibit the recombinantmouseTNF-
binding to its antibody with an IC50 of 16.5M. Furthermore, in
silico docking suggested a binding mode of BIHC similar to a
ligand known to disrupt the native, trimeric structure of TNF,
and also validated with molecular dynamics simulations. More-
over, we have demonstrated the down-regulation of p65 phos-
phorylation and other NF-B-regulated gene products upon
BIHC treatment, and on the phenotypic level the compound
shows inhibition of CXCL12-induced invasion of HepG2 cells.
Also, we demonstrate that BIHC inhibits infiltration of macro-
phages to the peritoneal cavity and suppresses the activity of
TNF- in vivo in mice primed with thioglycollate broth and
lipopolysaccharide. We comprehensively validated the TNF-
inhibitory efficacy of BIHC in an inflammatory bowel disease
mice model.
Tumor necrosis factor (TNF, also called TNF-) is a proin-
flammatory cytokine involved in multiple biological processes
including immune system regulation, cell proliferation, and
survival (1). TNFwas originally identified as an anti-tumor pro-
tein produced bymacrophages in 1975 (2); however, later stud-
ies have shown that it can be produced by several types of cells
including natural killer cells, B and T lymphocytes, mast cells,
neutrophils, endothelial cells, muscle cells, etc. (3). Function-
ally, TNF is a cell-derived inflammatory mediator produced in
response to bacterial antigens, such as lipopolysaccharide (LPS)
(4). During chronic inflammation, however, an exaggerated
immune response involving the production of TNF is able to
dysregulate a variety of signaling cascades, and thereby contrib-
ute to oncogenesis (5). TNF is functional in its trimeric form
and is known for its specific and efficient activation of nuclear
factorB (NF-B) signaling pathway that has been closely asso-
ciated with carcinogenesis (6, 7). Researchers have hence iden-
tified TNF as a “master switch” that plays a pivotal role in the
link between inflammation and cancer.
NF-B is a transcription factor known to transcribe more
than 200 genes involved in inflammation, cell proliferation, and
* This work was supported by grants from National University of Singapore
(NUS) Academic Research Fund (Grant R-184-000-207-112) (to G. S.). This
researchwasalso supportedby theUniversityGrantsCommission (41-257-
2012-SR), Vision Group Science and Technology, and Department of Sci-
ence and Technology (Grant SR/FT/LS-142/2012) (to Basappa).
1 Both authors contributed equally to this work.
2 Recipient of a Basic Scientific Research (BSR) fellowship from the University
Grants Commission (UGC).
3 Recipient of an INSPIRE fellowship from the Department of Science and
Technology (DST).
4 Present address: Dept. of Studies and Research in Biochemistry, Tumkur
University, Tumkur 572 103.
5 Recipient of a PAVATE fellowship fromKarnatakaUniversity, India. Towhom
correspondence may be addressed. Tel.: 91-802-2961346; Fax: 91-80-
22961372; E-mail: salundibasappa@gmail.com.
6 To whom correspondence may be addressed. Tel.: 44-1223-762-983; Fax:
49-30-4849-898-43; E-mail: ab454@cam.ac.uk.
7 Recipient of DST (F.NO.SR/SO/HS-006/2010(G)), UGC (F.No.39-106/2010(SR)),
and Institution of Excellence (IOE) grants from the University of Mysore. To
whomcorrespondencemaybe addressed: Tel.: 91-821-2419666; Fax: 91-821-
2419363; E-mail: rangappaks@yahoo.com.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 289, NO. 46, pp. 31879–31890, November 14, 2014
© 2014 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.
NOVEMBER 14, 2014•VOLUME 289•NUMBER 46 JOURNAL OF BIOLOGICAL CHEMISTRY 31879
 by guest on O
ctober 20, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
survival, which include the Bcl-2 family proteins, Mcl-1, cyclin
D1, survivin, cyclooxygenase-2 (COX-2),matrixmetalloprotei-
nases (MMPs), c-Myc, interleukins, growth factors, and cell
adhesion molecules (8). It is present in the cytoplasm, either in
its homodimeric or in its heterodimeric form, and associated
with an inhibitory peptide, inhibitory B (IB) (9, 10). A ubiq-
uitin-mediated degradation of inhibitory IB protein and
phosphorylation of various serine residues can then lead to
nuclear translocation with subsequent effects on transcription
(11). NF-B1 (p50), NF-B2 (p52), RelA (p65), RelB, and c-Rel
are the five types of NF-B subunits that have been identified
until the current stage, out of which the p50-p65 heterodimer is
the most common heterodimer associated with IB (12).
Given that small regulatory changes to NF-B signaling may
contribute to tumorigenesis (13) a manipulation of TNF-medi-
atedNF-B signaling by smallmolecules could be a potent ther-
apeutic strategy to combat inflammatory diseases, as well as to
combat associated consequences of cancer development.
Currently, several monoclonal antibodies as well as synthetic
and natural chemical moieties have been identified as TNF
blockers (14). 2,5-Dimethoxy-4-iodoamphetamine, xanthine
derivatives, and curcumin are some of the known small mole-
cules with anti-inflammatory effect that act via inhibiting TNF
expression and signaling (15–18). In addition, certolizumab,
infliximab, golimumab, and adalimumab are the monoclonal
antibodies used for this very purpose (19–22). On the disease
level, lactone and coumarins have also previously been reported
to interferewithNF-B signaling in several type of cancers (23).
In the context of the present study we have now synthesized
several novel biscoumarin derivatives and evaluated their anti-
proliferative efficacy against human hepatocellular carcinoma
(HCC)8 cells, and as a result, we were able to identify BIHC as a
potent cytotoxic agent. Furthermore, we predicted the putative
target of BIHC as TNF- using an in silico cheminformatics
approach, and this target was confirmed experimentally. We
subsequently evaluated whether BIHC can abrogate TNF-in-
duced NF-B signaling cascade in HCC cells and found that as
expected it caused down-regulation of p65 and its regulated
gene products. Additionally, ELISA-based TNF binding studies
revealed clear dose-response relationships between the con-
centration of BIHC and antibody binding of TNF-. Also, we
evaluated the effect of BIHC on the release of TNF by macro-
phages stimulated with lipopolysaccharide (LPS) in an in vivo
mouse model and observed a significant reduction in the levels
of TNF in the intraperitoneal fluid. Besides evaluating the role
of BIHC on TNF--induced NF-B signaling and in vivo anti-
inflammatory activities, we also found that the suppression of
dextran sodium sulfate (DSS) induced colitis in an inflamma-
tory bowel disease mouse model through the regulation of var-
ious cytokines. Hence, we are able to report overall the synthe-
sis, mode-of-action analysis, and comprehensive in vitro and in
vivo evaluation of novel biscoumarins as TNF- inhibitors.
EXPERIMENTAL PROCEDURES
Suppliers and Physical Measurements
Materials and reagents were purchased from commercial
suppliers and used as received.Melting points were determined
through open capillary method using Sigma melting point
apparatus and are uncorrected. IR spectra were recorded on a
Shimadzu IR spectrophotometer. 1H NMR and 13C NMR
spectra were recorded on an Agilent Varian spectrometer in
dimethyl sulfoxide (DMSO) at 400MHz using TMS as internal
standard, and chemical shifts are in . Mass spectroscopic anal-
ysis was done on a Shimadzu LC-MS. Analytical TLCs were
performed on precoated Merck 0.25-mm silica gel 60 F254
plates using 40% ethyl acetate in n-hexane as eluent, and the
spots were detected under UV light. Biological reagents such as
Hoechst 33342, MTT, Tris, glycine, NaCl, SDS, BSA, and -ac-
tin antibodywere purchased fromSigma-Aldrich.DMEM, FBS,
0.4% trypan blue vital stain, and antibiotic-antimycoticmixture
were obtained from Invitrogen. Antibodies against cyclin D1,
Bcl-2, survivin,Mcl-1, lamin B1, and PARPwere obtained from
Santa Cruz Biotechnology (Santa Cruz, CA). Antibodies to
phospho-specific p65 (Ser-536) and p65 were purchased from
Cell Signaling Technology (Beverly, MA). Goat anti-rabbit-
HRP conjugate and goat anti-mouseHRPwere purchased from
Sigma-Aldrich. CXCL12 was purchased from ProSpec-Tany
TechnoGene Ltd. (Rehovot, Israel). Dextran sulfate sodium salt
was obtained fromMPBiomedicals. Etacept was obtained from
CIPLA, Mumbai, India. Sulfasalazine was from Cadila Health-
care Ltd., Ahmedabad, India. Murinemini ELISA development
kits for TNF-, IFN-, IL-6, IL-1, and IL-10 were purchased
from PeproTech. All other chemicals were of analytical grade
and were purchased from Sisco Research Laboratories (SRL,
Mumbai, India).
Synthesis of Substituted Biscoumarins
General Procedure for One-pot Synthesis of bis-(4-Hydro-
xycoumarin)methanes—A mixture of (a) aromatic/heteroaro-
matic aldehydes (1 mmol), (b) 4-hydroxycoumarin (1.5 mmol)
and (c) thiamine hydrochloride (0.2 mmol) in 4–5 ml of water
was refluxed. The completion of reaction was monitored by
thin layer chromatography with the solvent system ethyl ace-
tate:hexane (4:6). After completion of the reaction, the reaction
mixture was brought to room temperature. The solid crude
product was separated by filtration, washed with water, and
dried to give pure products. Spectral properties are consistent
with the assigned structures.
Cell Lines—Human hepatocellular carcinoma cell lines
(HepG2 and Hep3B) were obtained from American Type Cul-
ture Collection (Manassas, VA). HCCLM3 cells were kindly
provided by Prof. KamMan Hui, National Cancer Centre, Sin-
gapore. All HCC cell lines were cultured in DMEM containing
1 antibiotic-antimycotic solution with 10% FBS.
MTT Assay—The anti-proliferative effect of biscoumarins
against HCC cells was determined by the MTT dye uptake
method as described previously (24). Briefly, the cells (5 103/
ml) were incubated in triplicate in a 96-well plate in the pres-
ence or absence of the indicated concentrations of compounds
in a final volume of 0.2 ml for different time intervals at 37 °C.
8 The abbreviations used are: HCC, hepatocellular carcinoma; BIHC, 3,3-((2-
butyl-5-chloro-1H-imidazol-4-yl)methylene)bis(4-hydroxy-2H-chromen-
2-one); DSS, dextran sulfate sodium; PARP, poly(ADP-ribose) polymerase;
MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; TG,
thioglycolate; DAI, disease activity index; RO, reverse osmosis; MPO,
myeloperoxidase.
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Thereafter, 20 l of MTT solution (5 mg/ml in PBS) was added
to each well. After a 2-h incubation at 37 °C, 0.1 ml of lysis
buffer (20% SDS, 50% dimethylformamide) was added, incuba-
tion was done for 1 h at 37 °C, and subsequently the optical
density at 570 nm was measured by a Tecan plate reader.
In Vitro TNF- Binding Assay—The binding of TNF- anti-
body binding was measured using a colorimetric-based Quan-
tikine ELISA kit (R&D Systems). Different concentrations of
BIHC (5–40 M) were incubated with recombinant mouse
TNF- for 30 min at room temperature, and then 100 l of the
reaction mixture was transferred to a 96-well plate coated with
a polyclonal antibody specific for mouse TNF- followed by
incubation for 2 h at room temperature. After washing, 100 l
of horseradish peroxidase-conjugated anti-TNF- antibody
was added to each well. After 30 min at room temperature, 100
l of a stop solution (diluted HCl) was added, and the optical
density of the streptavidin-POD enzyme conjugate was deter-
mined using a model 680 microplate reader (Bio-Rad) at 450
nm. Heparin (50 g/ml) was used as a positive control.
SPR Analysis—Interaction of TNF- with BIHC was exam-
ined using a Biacore-100 system. The TNF--immobilized sen-
sor chip was prepared as described previously (25, 26). HBS-EP
running buffer (10 mM HEPES, 0.15 M NaCl, 3 mM EDTA, and
0.005% (w/v) Tween 20, pH 7.4) having different concentra-
tions of BIHC (10, 20, 30, 40, and 50 M) was injected onto the
surface of the sensor chip coated with TNF-. Using the instru-
ment default protocol, the flow rate was kept at a moderate
speed of 30 l/min. BIHC was allowed to interact with TNF-
for 2 min. The kinetic parameters for the binding of BIHC with
TNF- were obtained using a 1:1 binding model with mass
transfer of BIA evaluation software.
In Silico Molecular Docking Studies—The co-crystal struc-
ture of TNF dimer with its inhibitor was used for structure-
based molecular docking studies (27). A small molecule
chromone-based compound has been reported to disrupt the
native trimer of TNF- binding to a dimeric complex, thereby
exposing the hydrophobic protein-protein interface (27). We
used the co-crystal structure of this compound and TNF- as
basis for our molecular docking studies (see Fig. 2A). We
docked the full series of 23 biscoumarins to the TNF- dimer
using the default settings in MOE as described earlier (7, 28).
We further evaluated the predicted bindingmode of BIHCby
performing amolecular dynamics simulation. Thus, we param-
eterized the ligand in the Generalized Amber Force Field (29)
and calculated point charges using Gaussian 03 (30) at HF/6-
31G* level and RESP fitting (31).We prepared the TNF- com-
plex using MOE, capped termini using acetyl and N-methyl
groups, and added a box of TIP3P water molecules (32) with
minimum wall distance of 10 Å. Simulations were performed
using the Amber force field 99SB-ILDN (33) using the GPU
implementation of pmemd in AMBER12 (34). After careful
equilibration including several minimization, heating, and
cooling steps (35) we performed 10 ns of unrestrained molecu-
lar dynamics simulation.
Western Blotting—For detection of various proteins, BIHC-
treatedwhole-cell extractswere lysed in lysis buffer (20mMTris
(pH 7.4), 250 mM NaCl, 2 mM EDTA (pH 8.0), 0.1% Triton
X-100, 0.01 mg/ml aprotinin, 0.005 mg/ml leupeptin, 0.4 mM
PMSF, and 4 mM NaVO4). Tissue lysate was prepared using
modified radioimmunoprecipitation assay buffer. Lysates were
then spun at 14,000 rpm for 10 min to remove insoluble mate-
rial and resolved on a 10% SDS gel. After electrophoresis, the
proteins were electro-transferred to a nitrocellulose mem-
brane, blocked with 5% nonfat milk, and probed with various
antibodies (1:1000) overnight at 4 °C. The blot was washed,
exposed to HRP-conjugated secondary antibodies for 1 h, and
finally examined by chemiluminescence (ECL; GE Healthcare,
Little Chalfont, Buckinghamshire, UK).
Invasion Assay—The in vitro invasion assay was performed
using the Bio-Coat Matrigel invasion assay system (BD Biosci-
ences), according to the manufacturer’s instructions (36). 1 
105 HepG2 cells were suspended in serum-free DMEM and
seeded into the Matrigel Transwell chambers consisting of
polycarbonate membranes with 8-m pores. After preincuba-
tionwith or without BIHC (25M) for 8 h, the Transwell cham-
bers were then placed into appropriate wells of a 24-well plate,
in which either the basal medium only or basal medium con-
taining CXCL12 had been added. After incubation for 24 h, the
upper surfaces of the Transwell chambers were wiped with cot-
ton swabs, and the invading cells were fixed and stained with
crystal violet solution. The invading cells were then counted in
five randomly selected areas under microscopic observation.
In Vivo Anti-inflammatory Studies—Adult Swiss albinomice
(20–25 g) were injected intraperitoneally with 2 ml of 3% thio-
glycolate (TG) broth (Sigma) or sterile saline as described ear-
lier (37). After 10 min, BIHC (0.5, 1.5 or 5 mg/kg) suspended in
saline was injected through a lateral tail vein. After 24 h, LPS
(1.0 g) was injected intraperitoneally, and 1 h later, the peri-
toneal cavities were lavaged with 4 ml of PBS containing 3 mM
EDTA. After the total number of inflammatory cells was
counted, the lavage fluid (2ml) was centrifuged at 1,500 rpm for
5 min, and the supernatant was stored at20 °C for the detec-
tion of TNF-. The amount of TNF-was determined by using
a Quantikine ELISA kit (R&D Systems). Heparin (10 mg/kg)
was used as a positive control.
Inflammatory Bowel Disease Model—6–8-week-old Swiss
albino mice weighing about 30–36 grams were kept in a 12-h
light and 12-h dark cycle and fed with standard chow formula
and reverse osmosis (RO) water and were acclimatized for 1
week. Colitis was induced by administering 5%DSS (w/v) in RO
water for 4 days to all the mice except RO control, Etacept
alone, Sulfasalazine alone, and BIHC alone. Themice were ran-
domly divided into nine groups (n  6), and each group
received the treatment from day 5 to day 9 as follows: Group 1,
RO water control; Group 2, DSS-treated; Group 3, DSS- and
Etacept-treated (5mg/kg/day, subcutaneously injected); Group
4, DSS- and Sulfasalazine-treated (500mg/kg/day, oral gavage);
Group 5, DSS- and BIHC-treated (2.5 mg/kg/day, intraperitoneal
injection); Group 6, DSS- and BIHC-treated (5 mg/kg/day, intra-
peritoneal injection); Group 7, BIHC alone (5 mg/kg/day, sub-
cutaneous injection); Group 8, Etacept alone (5 mg/kg/day,
subcutaneous injection); and Group 9, Sulfasalazine alone (500
mg/kg/day, oral gavage). All the animals were given free access
to ROwater after day 4 until the completion of the experiment.
Animals were euthanized at day 10 through cardiac puncture,
and blood was collected to assess the levels of various pro- and
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anti-inflammatory cytokines in serum. The colon was excised
from caecum to anus, flushedwith ice-cold phosphate-buffered
saline (10 mM, pH 7.4), and further processed for histological
analysis. The efficacy of BIHC against colitis was compared
with Etacept (standard TNF- inhibitor) and Sulfasalazine
(standard therapeutic agent for colitis).
Determination of Disease Activity Index (DAI)—DAI was
scored as described earlier by Cooper et al. (38). In brief, weight
loss, stool consistency, and gross bleeding are the three individ-
ual parameters considered to assign the score to determine
DAI. Stool consistency scored 0 for normal stool; 2 for loose
stool; and 4 for diarrhea. Rectal bleeding scored 0 for normal;
2 for occult bleeding; and 4 for gross bleeding. Lastly, sever-
ity of colitis in the colons were analyzed by measuring the
length of the colon, which is an indirect evidence of colonic
inflammation.
Myeloperoxidase (MPO)Activity—The excised colonic tissue
from all the groups were homogenized in 50 mM potassium
phosphate buffer pH 6.0 containing 0.5% hexadecyltrimethyl
ammoniumbromide. Tissue debris were removed by centrifug-
ing the homogenates at 3,000 rpm for 4 min at 4 °C. Superna-
tant (10 l) was taken in 96-well plate in triplicates, and 200 l
of ODA-H2O2 reagent (0.167 mg/ml o-dianisidine dihydro-
chloride and 0.05%H2O2) was added to each well including the
well containing 10 l of buffer alone, which served as blank.
Absorbance was measured at 450 nm using multimode plate
reader (Thermo Scientific) at 0, 30, and 60 S. The difference
between two time points was taken, and the MPO activity was
calculated using the formula (MPO constant: 1.13102).
Average of A0 –30 and A30 – 60
TimeMPO constant Tissue weight
(Eq. 1)
Estimation of SerumCytokine Levels—Themodulatory effect
of BIHC on the levels of pro- and anti-inflammatory cyto-
kines (TNF-, IFN-, IL-1, IL-6, and IL-10) were estimated
using ELISA kits according to the manufacturer’s protocol
(PeproTech).
Histological Evaluation—The colonic tissues were fixed
overnight in 10% phosphate-buffered formalin and dehydrated
by processing with alcohol and chloroform mixture. The pro-
cessed tissues were embedded in paraffin wax, and sections of
5-m thickness were prepared. Further sections were stained
with hematoxylin-eosin dye (H&E) and photographed under an
Axio Imager.A2microscope (Carl Zeiss AG, Oberkochen, Ger-
many). Themethod ofGonzalez-Rey et al. (39) was followed for
histological scoring of inflammation of colon section on a 0–3
graded scale: 0 for no sign of inflammation; 1 for low leukocyte
infiltration; 2 for moderate leukocyte infiltration, thickening of
the colon,moderate goblet cell loss, and focal loss of crypts; and
3 for transmural infiltration, massive loss of goblet cells, and
diffuse loss of crypts. Irrespective of the treatments each slide
was scored from five random spots.
Statistical Analysis—The statistical analysis was done using a
software Origin 8 (OriginLab). The Mann-Whitney U test was
used to determine p values.
RESULTS
Chemistry
7,7-Dihydroxy-6,6-dimethoxy-3,3-biscoumarin was isolated
from Erycibe obtusifolia (40). Additionally, the biscoumarin was
synthesized by the condensation of 4-hydroxycoumarin and
aldehydes using Et2AlCl (41) or tetra-n-butylammonium bro-
mide (TBAB) (42) as catalysts. Previously, microwave-assisted
or sonochemically (43) mediated catalyst-free condensation
reactions were reported. In the current work we employed the
thiamine hydrochloride-catalyzed condensation reaction of
4-hydroxycoumarins with aromatic, heteroaromatic, and ali-
phatic aldehydes for the synthesis of biscoumarin compounds.
Details of the condensation reaction between 4-hydroxycou-
marin and various aldehydes are summarized in Scheme 1 in
Fig. 1A. Upon treatment of 4-hydroxycoumarin and various
aldehydes reaction in the presence of thiamine hydrochloride
in refluxing water, took place within 4–8 h, giving white solid
products.
Biology
BiscoumarinAnalogs Suppress Proliferation ofHCCCells in a
Dose- and Time-dependent Manner—We evaluated the cyto-
toxic effects of the newly synthesized series of compounds on
HepG2 cells using the MTT assay. Among the tested com-
pounds, BIHCwas found to bemost effective with an IC50 value
of 6.4 M. Furthermore, we investigated whether BIHC can
inhibit the proliferation of various HCC cell lines, namely
HepG2, Hep3B, and HCCLM3, by using the MTT assay. BIHC
significantly inhibited the proliferation of all the threeHCC cell
lines in a dose- and time-dependent manner (Fig. 1, B–D).
In Silico Mode-of-action Analysis of BIHC—Human protein
targets were predicted for BIHC, which was shown to have the
highest anti-proliferative effect in the HCC cell line HepG2
(IC50 6.4M). For this purpose, we employed in silico target
prediction algorithms, which are trained on known bioactiv-
ity data and which have been successfully applied in different
situations before (44, 45). We employed a Laplacian-modi-
fied Naïve Bayes classifier as published previously (46). Five
targets were predicted with a log-odds score exceeding the
cut-off of 5. Given the well established role of TNF in cancer
as described in previous studies (47, 48) this target was cho-
sen for further computational as well as experimental
analysis.
In Silico Interaction Studies of Biscoumarins with TNF—A
small molecule inhibitor of TNF-, namely 6,7-dimethyl-3-
[(methyl{2-[methyl({1-[3-(trifluoromethyl)phenyl]-1H-indol-
3-yl}methyl)amino]ethyl}amino)methyl]-4H-chromen-4-one
(DIC), which promotes subunit disassembly of the trimeric cy-
tokine family member, has been reported previously (27) (Fig.
2A). Using in silico docking (as described under “Experimental
Procedures”) we found that all 23 biscoumarins seem to occupy
similar regions of the binding pocket (see Fig. 2C for the pre-
dicted binding pose of BIHC showing highest binding affinity).
Docking scores correlated to a good extent with molecular
weight (r2 0.62), as expected in a hydrophobic environment,
which is lacking distinct anchor points for smallmolecule bind-
ing. Therefore, we did not attempt to rationalize binding affin-
ANovel Biscoumarin That Disrupts TNF Signaling
31882 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 289•NUMBER 46•NOVEMBER 14, 2014
 by guest on O
ctober 20, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
ities and particular ligand-protein interactions in more detail.
Strikingly, we found the most active compound BIHC to show
the lowest strain energy in comparison with all other com-
pounds in the series. Hence, we hypothesize that conforma-
tional aspects seem to be crucial for small molecule binding to
TNF-. We furthermore performed an unrestrainedmolecular
dynamics simulation to investigate the predicted bindingmode
frommolecular docking. We found the complex to be very sta-
ble with a root mean square deviation of C positions smaller
than 1.5 Å. Although the ligand is highly flexible in the hydro-
phobic binding interface, it remains close to the predicted bind-
ing mode over the full trajectory length of 10 ns (Fig. 2B).
Therefore, the predicted bindingmode of BIHC in the interface
of TNF- is overall found to be plausible and appears to be
dominated by hydrophobic (and overall rather unspecific)
interactions.
FIGURE 1. Synthesis (A) and cytotoxicity evaluation (B–D) of novel biscoumarins toward HCC cells. A, scheme represents the synthesis of biscoumarins
(R-aromatic/heteroaromatic group). Twenty-threenewbiscoumarinderivativesweredesignatedas 3(a-w). Theanti-proliferative effects of BIHCagainstHepG2
(B), HCCLM3 (C), and Hep3B (D) cells were determined byMTT assay and reported as the percentage of viable cells relative to the control. Values are means
S.E. of three independent experiments. * indicates p value 0.05.
FIGURE 2. In silico and in vitro analysis of the lead compound on TNF structure and functionality. A, the x-ray structure of TNF- (yellow and blue graphic)
and a smallmolecule inhibitor (all smallmolecules shownas sticks in element-wise coloring, carbonatoms ingreen) is shown. Six aromatic residues are exposed
in the interface and are shown in stick representation. B, predicted binding mode of BIHC occupying a similar region in the hydrophobic binding site. C,
ensemble of 10 snapshots from amolecular dynamics simulation of BIHC in the binding site highlighting flexibility of the ligand in the hydrophobic environ-
ment. D, the inhibitory effects of BIHC on the binding of TNF- to anti-TNF- antibody. Recombinant mouse TNF- was incubated with the indicated
concentrationsof BIHC (5–40M). TheboundTNF-wasquantifiedusing theQuantikine kit. Thepercentageof inhibitionof thebindingof TNF- to anti-TNF-
antibody against the concentration of BIHC is shown. Heparin (50 g/ml) was used as a positive control. Data are represented as the mean  S.D. for four
replicates. * indicates p value 0.05, and ** indicates p value 0.01.
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Inhibitory Effect of BIHC on TNF-/anti-TNF- Antibody
Binding—Todeterminewhether BIHC can block the binding of
TNF- to its antibody, and hence lend support to the target
predicted in silico, BIHC was incubated in vitro with recombi-
nant TNF- and its inhibitory effect was quantified. It was
found across a dose range from 5 to 40 M that BIHC inhibited
the binding of TNF- to its antibody in a dose-dependentman-
ner, resulting in an IC50 value of 16.5 M (Fig. 2D).
SPR Analysis of BIHC with TNF—We analyzed the interac-
tion between BIHC and TNF- via SPR analysis using the
Biacore system. The N terminus of TNF-was immobilized on
the streptavidin-coated sensor chip. The injection of different
concentrations of BIHConto the surface of a sensor chip coated
with TNF- resulted in the sensorgrams as shown in Fig. 3A.
8.5 1.5 103 M1 s1 as association and 3.2 0.7 103 s1
as dissociation rate constantswere obtained for the BIHC inter-
action with TNF-. The dissociation equilibrium constant (Kd)
was found to be 21.4 M, signifying the affinity of BIHC toward
TNF-.
BIHC Down-regulates the Expression of Cyclin D1, Mcl-1,
Survivin, and Bcl-2 in HCC Cells—NF-B activation has been
shown to regulate the expression of various gene products
involved in cell survival, proliferation, angiogenesis, and
chemoresistance (10). We found that the cell cycle regulator,
cyclin D1, and the anti-apoptotic proteins, Mcl-1, survivin, and
Bcl-2, were constitutively expressed in HCC cells. However,
their expression decreased in a time-dependent manner upon
BIHC treatment, with maximum suppression observed at
around 72 h (Fig. 3B). This also supports our hypothesis of
TNF- as a target of this compound.
BIHC Causes PARP Cleavage in HCC Cells—Whether sup-
pression of constitutively active NF-B inHepG2 cells by BIHC
leads to apoptosis was investigated in the next step so that func-
tional conclusions with regard to compound action could also
be drawn. It was found that BIHC treatment of HepG2 cells
resulted in time-dependent impact on cleavage of a 116-kDa
PARP protein into an 85-kDa fragment (Fig. 3B). Given the
biological role of PARP these results clearly suggest that BIHC
induces substantial apoptosis in HepG2 cells.
BIHC Inhibits Phosphorylation and Translocation of p65 in
HCC Cell Lines—In the next step we investigated the effect of
BIHC on the constitutive phosphorylation of p65, given that
phosphorylation is required for its transcriptional activity (9,
10). HepG2 cells were preincubated with different concentra-
tions of BIHC, and nuclear extracts were prepared and tested
for p65 phosphorylation and translocation using Western blot
analysis. As shown in Fig. 3C, BIHC treatment abrogated both
p65 phosphorylation and translocation in a time-dependent
manner, with maximum inhibition seen at 12 h.
BIHC Inhibits CXCL12-inducedHCCCell Invasion—Wealso
determined the effect of BIHC on HCC cell invasion, a key
hallmark of cancer. Using an in vitroBoyden chamber assay, we
found that HepG2 cells invaded faster under the influence of
CXCL12 (Fig. 4). To elucidate further the effect on BIHC on
CXCL12-induced cell invasion, we used BD BioCoat Matrigel
invasion assay system and found that the treatment with BIHC
significantly suppressed CXCL12-induced invasion of HepG2
cells (Fig. 4).
Effect of BIHC on the Secretion of TNF- in Vivo—The effects
of BIHC on the local production of TNF- in the peritoneal
cavities of TG-treatedmice were examined to confirm the anti-
FIGURE3.A, interactionof BIHC towardTNF-. Various concentrationsof BIHC
(10–50 M) were injected onto the surface of a TNF--immobilized sensor
chip. Obtained sensorgramswere overlaid using the BIA evaluation software.
RU, resonance units. Long and short arrows represent the beginning of the
association and dissociation phases, respectively. B, BIHC suppresses NF-B-
regulatedgeneproducts involved inproliferation, survival, andangiogenesis.
HepG2 cells (2 106/ml) were treatedwith 25M BIHC for the indicated time
intervals, after which whole-cell extracts were prepared, 30 g of proteins of
those extracts was resolved on 10% SDS-PAGE, and membrane was sliced
according to molecular weight and probed against PARP, cyclin D1, Mcl-1,
survivin, and Bcl-2 antibodies. The same blots were stripped and reprobed
with-actin antibody to verify equal protein loading. The results of cyclin D1,
Survivin, and Bcl-2 shown are representative of two independent experi-
ments. C, HepG2 cells (2  106/ml) were treated with 25 M BIHC for the
indicated time intervals, after which whole-cell extracts were prepared and
30gofproteins of those extractswas resolvedon10%SDS-PAGE, andmem-
brane was sliced according to molecular weight and probed against phos-
pho-p65 antibody. The same blots were stripped and reprobedwith p65 and
lamin B1 antibodies.
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inflammatory role of BIHC. BIHC effectively inhibited the infil-
tration of inflammatory cells in the lavage fluid by 47, 55, and
64% at 0.5, 1.5, and 5mg/kg, respectively, as compared with the
control (Fig. 5A). Heparin (10 mg/kg), which was used as a
positive control, inhibited the infiltration of inflammatory cells
in the lavage fluid by 81%. In addition, higher levels of TNF-
were detected in the mice primed with TG and LPS as com-
pared with saline-injected control mice. TNF- release was
reduced from 42 (control) to 26, 22, or 19  102 ng/ml, cor-
responding to 38, 46, and 55% reduction as compared with the
control at 0.5, 1.5, and 5 mg/kg of BIHC, respectively (Fig. 5B).
Heparin, the positive control, inhibited TNF- release from 42
to 12  102 ng/ml, corresponding to 70% reduction at 10
mg/kg of dose. These results support the effects of the direct
binding of BIHC to TNF-.
Effect of BIHC on DSS-induced Disease Activity Index, Colon
Length, andMPOActivity—The severity of DSS-induced colitis
was monitored by assessing the DAI throughout the experi-
mental period. We observed the increase in DAI in the animals
administered with DSS as compared with control group (Fig.
6A). After day 6, DAI was significantly decreased in the groups
treated with BIHC (p 0.01), Etacept (p 0.01), and Sulfasala-
zine (p  0.01) in comparison with the DSS control group.
Animals treated with a higher dose of BIHC (5 mg/kg of body
weight) showed better recovery than its counterpart (2.5mg/kg
of body weight). We also observed the significant reduction in
length of the colon in DSS-induced animals (Fig. 6B). On the
other hand, treatment with BIHC, Etacept, and Sulfasalazine
showed a substantial increase in length of the colon as com-
pared with DSS control group. As an index of colonic inflam-
mation, neutrophil infiltration was assessed via MPO activity
from the colons of the control and DSS-induced experimental
animals. The results revealed a significant (p 0.001) increase
in the activity of MPO in the colons of DSS-induced mice in
comparison with RO control (Fig. 6C), signifying the severe
intestinal inflammation. In contrast, treatment with BIHC, Eta-
FIGURE 4. A, cell invasion assay for evaluating the inhibitory effect of BIHC on
HepG2 cell invasion. HepG2 cells were pretreatedwith CXCL12 (20M for 2 h)
followed by incubation with BIHC for 8 h. The cells were also treated with 25
MBIHCalone for 8horCXCL12 (20M for 2h) alone. The cellswere fixedwith
4% paraformaldehyde before staining with 0.5% crystal violet as
described under “Experimental Procedures.” B, the percentage of the
migratory cells of the treated groupwas normalized against the untreated
group. The values are themeans S.E. of three independent experiments.
*, p  0.05.
FIGURE 5. In vivo anti-inflammatory activity of BIHC. A, the anti-inflamma-
tory effects of BIHC on TG	 LPS-induced inflammation in mice. Swiss albino
mice were injected intraperitoneally with 2ml of 3% TG and LPS (1g). Intra-
venous administration of BIHC (0.5, 1.5, or 5 mg/kg) and heparin (10 mg/kg)
effectively suppressed the inflammation. The bar graph represents the per-
centage of inhibition of the infiltration of inflammatory cells into the perito-
neal fluid by BIHC and heparin. B, the effects of BIHC (0.5, 1.5, or 5mg/kg) and
heparin (10mg/kg) on the local productionof TNF- in theperitoneal cavities
of themiceprimedwith TGandLPS.Data from thequantificationof TNF- are
presented as the mean S.D. for three independent experiments, and each
experiment was conducted with six mice per group. *, p 0.05, and **, p
0.01 versus control.
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cept, and Sulfasalazine showed a substantial (p 0.001) reduc-
tion in MPO activity in the colons as compared with animals
treated with DSS alone, indicating the anti-inflammatory
potential of BIHC.
Effect of BIHC on Histopathology—We carried out the histo-
pathological examination of colons using H&E staining (Fig.
7A) and assigned the scores to present in the formof a bar graph
(Fig. 7B). We observed the distortion of the cryptic epithelium,
as well as mucosal and submucosal infiltration of inflammatory
leukocytes in the colon of DSS-induced animals (Fig. 7A, panel
ii), whereas the animals treated with BIHC (5 mg/kg of body
weight) (Fig. 7A, panel iii) displayed normal architecture with
epithelial crypt structures and lesser infiltration of inflamma-
tory leukocytes, which was highly comparable with Etacept
(Fig. 7A, panel iv)- and Sulfasalazine (Fig. 7A, panel v)-treated
animals.
Effect of BIHC on DSS-induced Secretion of pro- and anti-
inflammatory Cytokines—Cytokines play a critical role in the
progression of colitis, and essentially an imbalance in the levels
of pro- and anti-inflammatory cytokinesmay prevent the prog-
nosis of colitis. The levels of pro- and anti-inflammatory cyto-
kines from serum of all the groups were estimated using ELISA
kits. It was apparent that the levels of pro-inflammatory cyto-
kines (TNF-, IFN-, IL-1, and IL-6) were notably increased
(p  0.01) and the anti-inflammatory cytokine (IL-10) was
decreased (p 0.01) in DSS-induced animals (Fig. 8, A–D). In
contrast, animals treated with BIHC (5 mg/kg of body weight),
Etacept, and Sulfasalazine significantly (p 0.01) reverted back
the DSS-induced pro- and anti-inflammatory cytokines. These
data were further supported by immunoblotting of colon tissue
homogenate against TNF- antibody. Colon tissue homoge-
nate of the mice treated with DSS alone exhibited elevated lev-
els of TNF-, whereas colon homogenate of the mice treated
with BIHC (5mg/kg of body weight), Etacept, and Sulfasalazine
exhibited substantially decreased elevated levels of TNF- (Fig.
8E).
DISCUSSION
TNF is reported to be elevated in several types of cancer and
one of the leading causes of inflammatory diseases, which ren-
ders it a potential therapeutic target in this context (49–51).
The current study focuses on the synthesis of a library of novel
biscoumarins, the identification of its most potent member,
which was BIHC, the computational prediction of its putative
mode of action and its validation, as well as the comprehensive
biological characterization of the compound.
Our cheminformatics approach presented as a predicted tar-
get TNF-, and further structure-based analysis was able to
develop a hypothesis for the interaction of BIHC with dimeric
TNF. To validate the predicted target we evaluated the inhibi-
tory activity of BIHCby anELISA-based in vitroTNF- binding
assay. Results showed a dose-dependent inhibition of antibody
binding, comparable with heparin, with an IC50 of 16.5 M.
Furthermore, the SPR analysis revealed interaction of BIHC
with TNF-, signifying the preference of biscoumarins over the
inflammatory marker. Given that TNF signaling activates a
series of cytoplasmic kinases, which finally phosphorylate sub-
units of NF-B (10), we then evaluated phosphorylation levels
of p65 in HepG2 cells treated with BIHC and found that they
decrease in a time-dependentmanner. NF-B is a transcription
factor that transcribes the cluster of genes coding various pro-
teins involved in cell survival, angiogenesis, anti-apoptosis, and
FIGURE 6. Effect of BIHC on DSS-induced DAI, colon length, and MPO
activity. A, the severity of DSS-induced colitis wasmonitored daily by assess-
ing the DAI throughout the experimental period. From day 4 onward DSS
induced a significant increase in DAI. SZ: Sulfasalazine. B, severity of the
colonic inflammation was assessed indirectly by measuring the colon length
of RO control and experimental mice. C, severity of colonic inflammationwas
assessed by colonic MPO activity from RO control and experimental mice.
Data are presented asmean S.E. *, p 0.05, **, p 0.01; ***, p 0.001; n
6; a: significant in comparison with RO control; b: significant in comparison
with DSS control.
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metastasis (7, 52), and to assess the functional impact we then
profiled the expression pattern of NF-B-regulated gene prod-
ucts (Mcl-1, survivin, Bcl-2, cyclin D1) upon BIHC treatment,
where we observed a significant decline of anti-apoptotic pro-
teins. Furthermore, we confirmed the apoptosis-inducing
effect of BIHC by detecting cleavage of pro-PARP. Given that
NF-B also transcribes genes encoding proteins withmigratory
function we have furthermore confirmed that BIHC substan-
tially reduced cell migration upon CXCL12 stimulation.
Furthermore, we were also able to gather in vivo supports for
the effects described above in vitro. For this, we injected TG
broth intraperitoneally to adult Swiss albinomice to induce the
infiltration of immune cells. Upon administration of LPS to
TG-injected mice high levels of TNF in the lavage fluid col-
lected from peritoneal cavity were observed. In the mouse
group treated with BIHC, the levels of TNF have been signifi-
cantly reduced, in a dose-dependent manner, comparable at
high doses to heparin treatment.
In addition tomonoclonal antibodies, several synthetic small
molecules and phytochemicals have been studied extensively as
TNF- inhibitors in developing therapeutic agents against var-
ious cancers and inflammatory diseases (13, 53, 54). A wide
array of phytochemicals including flavonoids (butein, quer-
cetin), polyphenols (curcumin, capsaicin), alkaloids (piperine,
berberine), and terpenoids (lactones) have been implemented
in this direction (54). Although these natural compounds inter-
ferewithTNF signaling, they largely exhibit non-specificity and
induce their effect in a multifactorial way. For instance, curcu-
min has been demonstrated to induce its inhibitory effect on
TNF-, JAK-STAT, JNK, NF-B, and MAPK signaling path-
ways, suggesting the diverse targets of natural compounds (55–
57). On the other hand, BIHC specifically inhibits the TNF sig-
naling, thereby contributing to suppression of cancer cell
proliferation.
Finally, to provide the direct evidence on structural distor-
tion of TNF-, we demonstrated the effect of BIHC on TNF--
FIGURE 7. A, histopathological images (100) of H&E-stained colon cross sections of RO control mice and DSS-induced mice treated with BIHC, Etacept, and
Sulfasalazine. Panel i, colon section of the RO control mice showing normal crypt structures with intact mucosal and submucosal epithelium. Panel ii, colon
section of the DSS-treated mice showing severe transmural inflammation and distorted crypt epithelium along with mucosal and submucosal infiltration of
inflammatory cells. Panels iii–v, representative colon sections of the DSS-induced mice treated with BIHC, Etacept, and Sulfasalazine, respectively, showing
restoration of crypt epithelial degeneration alongwith lesser infiltration of inflammatory cells. B, DSS treatment severely increased the histopathological score
in comparisonwith ROcontrol. Treatmentwith BIHC, Etacept, andSulfasalazine (SZ) significantly reduced theDSS-inducedhistopathological scores. Scores are
presented as mean  S.E. of five independent observations of colon sections. ***, p  0.001; a: significant in comparison with RO control; b: significant in
comparison with DSS control.
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induced inflammation in an inflammatory bowel diseasemouse
model and compared it with anti-inflammatory drugs such as
Etacept (Etanercept) and Sulfasalazine. Early treatment strate-
gies in ulcerative colitis employ the use of corticosteroids and
5-aminosalicylic acid derivatives (Sulfasalazine drugs), and the
disease at the advanced stage demands the use of high potential
therapeutics such as monoclonal antibodies (Etanercept, Ada-
limumab) (58, 59). Despite the fact that Sulfasalazine drugs and
monoclonal antibodies against TNF are the plausible remedy
for ulcerative colitis, the long term use of the formermay result
in nausea, flatulence, and diarrhea, and the latter may induce
neoplastic transformation and severe immunosuppression.
Therefore, designing and development of new selective TNF-
inhibitors is critically essential to override the harmful side
effects of existing therapeutics. In the present study, intraperi-
toneal injection of BIHC at a dose of 5 mg/kg of body weight
(approximately equivalent to a 300-mg dose in a 60-kg human)
into colitis-induced mouse resulted in a substantial decrease in
disruption of mucosal barrier, crypt architecture, disease activ-
ity index, and myeloperoxidase activity, as well as a substantial
increase in colon length, which is highly significant and
comparable with Etacept and Sulfasalazine. Furthermore,
the reversal of pro- and anti-inflammatory cytokines in the
BIHC-treated group is an additive evidence to demonstrate
the mode of action of BIHC. In summary, herein we describe
the synthesis, mode-of-action analysis, and in vitro and in
vivo activity of a novel biscoumarin small molecule that tar-
gets TNF-.
Acknowledgments—We thank Gajanan D. Katkar, Paul M, Naveen
Kumar SK, and Jagadish S for kind help during the study.
FIGURE 8. Effect of BIHC on DSS-induced secretion of pro- and anti-inflammatory cytokines. Serum cytokines levels of experimental animals were
estimatedusingmurinemini ELISAdevelopment kits according to themanufacturer’s protocol.A–E, levels of serumcytokines: TNF- (A); IFN- (B); IL-1 (C); IL-6
(D); and IL-10 (E). SZ, Sulfasalazine. F,Western blot of TNF- expression in colon tissues. Data are presented asmean S.E. of five independent experiments. *,
p 0.05, **, p 0.01; a: significant in comparison with control; b: significant in comparison with DSS control.
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